Friday, February 2, 2018

Barnett Jr. Named March Opponent for Salinas; Taylor Set for Ring Return

According to BoxRec.com, Alejandro Popo Salinas has his next victim within sights as Reggie Barnett Jr. has been named the opponent for the March 24th bout scheduled to take place at the Palermo Center in Campbell.

Salinas, 23, is on a six-match winning streak and will be looking to win some hardware in his scheduled 8-round match with Barnett as the vacant USA Mid American Super Featherweight Title will be on the line.

Barnett, 31, holds a record of 6-1 while the Chesapeake, Virginia native is on a current win streak of his own having won his previous three bouts.

This will be the first match for Salinas since he defeated Duarn Vue by decision at The Cannery in Las Vegas live on Fox Sports 1 in September to improve his record to 9-1.
Anthony Taylor

Also slated to appear on the card is Warren native Anthony Taylor.

Taylor, 26, has been inactive since May as the super flyweight is slated to take on Jesus Rojas of Columbus, Ohio by way of  Brooklyn, New York.

Rojas, 25, currently holds a 2-3-1 record while Taylor will bring a 4-2 record into the bout.

We will have more details as they become available including ticket information.


1 comment:

  1. One of the key factors is the high blogcost of research and development. Generic drug manufacturers have much lower operating costs than branded blogdrug manufacturers. This is due to the fact that drug discovery is expensive and the manufacturing of a drug will take years—costs that generic manufacturers do not have. blog After a company develops a medication, it must conduct costly clinical trials to ensure that the drug is both safe and effective. As a result, by the time the FDA approves a brand-name medication, blog the drug manufacturer has already invested millions. The risks associated with producing bloga new medication are not borne by generic drug producers. The drug's formula is known, the clinical trials are complete, and generic drug manufacturers are only investing in the manufacturing of the medicine, blogenabling them to market it at low prices. the market for a decade or more (the era during which the patent was valid), and patients and caregivers may already be familiar with blogthem. Costs are also held down by rivalry among generic drug manufacturers. Multiple companies begin manufacturing and selling generic drugs after they have been licensed. As a result, competition rises, blogallowing the price to stay stable.

    ReplyDelete